Tag Archives: dailyprompt

Cross-Border Investor Luncheon at RESI Boston 2026

21 Jul

A private, screened luncheon for regional and international investors seeking syndicate partners.

RESI Boston | Wednesday, September 23 | 75 Seats

RSVP for Cross-Border Investor Luncheon Today

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Nearly nine out of ten life science startups fail. Not because the science is poor, but because they never connect to the right capital and strategic partners. Solving that is the reason Life Science Nation exists, and for more than fifteen years our work has come down to one thing: finding parties who need each other and matching them.

As some readers know, LSN has been addressing this pervasive dilemma through the LSN Labs Anchor Node Program. An Anchor Node combines LSN’s commercialization methodology and global capital formation network with a regional partner’s laboratories, entrepreneurial programs, and operating platform to produce investment-ready life science companies.

As we expanded the Anchor Node Program across Boston, Australia, Japan, Korea, the UK, and Brazil, a clear pattern emerged: regional partners constantly brought their local VCs to the table seeking international capital. At the same time, our own data across five global RESI events revealed that twenty percent of all partnering meetings were already investor-to-investor.

So we decided to formalize it, and provide a dedicated room for these partners to connect.

The Cross-Border Investor Luncheon, CBIL, is a private luncheon at RESI Boston for regional and international investors seeking syndicate partners. Regional investors have access to exceptional companies that often never reach international investors. International investors have access and reach that regional funds cannot build alone. Both are looking for the same thing across Asia, Europe, North America, and South America.

Attendance is screened. CBIL is for active investors seeking syndicate partners outside their own region, whether that means bringing international capital into local deals or gaining access to deal flow in regions where they have no presence.

Taking place on Wednesday, September 23, CBIL follows the format of the Global Family Office BioForum luncheon (GFOB luncheon takes place on Tuesday, September 22), now in its eighth year. Across those eight years, GFOB has brought family offices together to find each other, form alliances, and build syndicates. CBIL is the natural next step, applying the same private, curated format to the international investor community.

“The future of life science investing is not just finding great companies. It is finding great syndicate partners in the global arena.”


Dennis Ford, Founder and CEO, Life Science Nation

Wednesday, September 23   |   Private luncheon   |   Screened RSVP   |   75 seats

Every RSVP is reviewed. Request your seat today!

RSVP for Cross-Border Investor Luncheon Today

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , ,

Finding the Right Investors Starts with the Right Data 

21 Jul

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

For early-stage life science companies, fundraising success depends on connecting with investors who are actively looking for technologies like yours. That is why Life Science Nation (LSN) has spent years building one of the industry’s most comprehensive investor databases, designed specifically to help innovators identify the right capital partners.

Unlike generic databases built through web scraping, the LSN Investor Database is curated directly through 1:1 interviews with investors and strategic in-licensors, providing startups with insights that go far beyond basic contact information or what you find on an investor’s website. Each investor profile includes valuable details such as typical check size, preferred modalities and indications, stage of development, geographic focus, and more, allowing companies to build a highly targeted fundraising strategy.

The database includes more than 4,000 global investment firms across 10 distinct investor categories and over 12,000 investor contacts spanning therapeutics, medical devices, diagnostics, digital health, and other life science sectors. Whether you are raising a Seed, Series A, or Series B round, identifying investors who are an actual fit can save significant time and improve the quality of your outreach.

Not sure where to begin? Life Science Nation is offering a complimentary investor search to help companies uncover potential investors that may not already be on their radar. The search demonstrates how the LSN Investor Database can provide each company with a curated list of investors matched to their technology and stage of development, along with contact information to then go out and execute on a fundraising campaign.

LSN is also happy to offer a free Fundraising Readiness Assessment through our internally developed AI Agent. The assessment will generate a 6-page report that can be used to help transition your companies’ story from an “interesting technology” into a compelling and ultimately investable company.

Book your free investor search today or complete the AI assessment to take the first step toward building a more focused and effective fundraising campaign.

Book Your Free Investor Search Today

Tags: , , , , , , , , , , , , , , ,

Registration Now Open for RESI JPM 2027 

7 Jul

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is excited to announce that registration is now open for RESI JPM 2027, taking place January 11–12 at the San Francisco Marriott Marquis, followed by three days of virtual partnering on January 13, 18, and 19. 

Held alongside the world’s largest gathering of healthcare investors, executives, and innovators during JPM Week, RESI JPM provides early-stage life science companies with a unique opportunity to raise capital, build strategic partnerships, and accelerate business development in one of the industry’s most active networking environments. 

Previous RESI JPM conferences welcomed more than 1,000 attendees, including over 600 active investors, strategic partners, pharmaceutical business development professionals, and industry leaders. The conference combines curated educational programming with one-on-one partnering meetings, creating meaningful opportunities for fundraising companies to connect directly with the investors and partners best aligned with their technologies. 

The expanded format begins with two full days of in-person programming at the San Francisco Marriott Marquis, featuring investor panels, educational workshops, the Innovator’s Pitch Challenge, networking events, poster presentations, and partnering meetings. The conference then continues online with three additional days of virtual partnering, allowing participants to maximize the number of meetings they can schedule while extending networking opportunities beyond the in-person event. 

Whether you are seeking Seed, Series A, or Series B financing, exploring strategic partnerships, licensing opportunities, or looking to expand your visibility within the life science investment community, RESI JPM offers multiple ways to engage. Registration options are available for startups, fundraising executives, service providers, technology hubs, exhibitors, and qualified investors. 

Early Bird registration is now available, offering substantial savings on five-day hybrid registration for startups and fundraising executives. Register early to lock in the lowest available rates. 

Organizations looking to maximize their visibility during JPM Week can also take advantage of sponsorship and exhibition opportunities designed to connect brands with a highly targeted audience of investors, innovators, and industry leaders. 

Register today and save up to $900 with Super Early Bird pricing!

Register Now

Don’t miss your opportunity to be part of one of the life science industry’s premier fundraising and partnering events. 

Tags: , , , , , , , , , , , , , , ,

Build Your Brand at the Expanded Two-Day RESI Boston

30 Jun

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Following the success of RESI San Diego, sponsorship opportunities are now available for RESI Boston, taking place September 22–23 during Biotech Week Boston. With two days of in-person programming, followed by three days of virtual partnering, RESI Boston offers even more opportunities to connect with the global life science investment community.

RESI San Diego welcomed an outstanding group of sponsors representing every corner of the life science ecosystem. Title Sponsors included Innopolis Jeonbuk Innovation Cluster, Biometas, and Korea Bio Innovation Center (KBIC). Gold Sponsors RSM and Medmarc shared their expertise through thought leadership and networking, while Silver Sponsors Biocytogen, Foley Hoag, and Polsinelli connected with innovators and investors throughout the conference. Additional support from Bronze Sponsors BSR Korea, JABI, Jeongup Si, Jeonbuk State, the Ministry of Science and ICT (Korea), Alithia Life Sciences, and Inertia further strengthened the event’s international reach.

Sponsoring RESI is more than displaying your logo. Sponsors gain visibility before, during, and after the conference through digital marketing, onsite branding, exhibit opportunities, educational programming, and access to RESI’s partnering platform. Whether your organization is looking to generate business leads, recruit new clients, showcase a regional innovation ecosystem, or establish thought leadership, RESI provides direct access to founders, investors, strategic partners, and service providers actively shaping the future of life sciences.

The expanded two-day in-person format at RESI Boston means more networking, more meetings, more educational sessions, and more opportunities for meaningful engagement than ever before. Combined with virtual partnering that continues after the event, sponsors benefit from sustained visibility and valuable follow-up opportunities well beyond the conference itself.

Ready to elevate your brand at RESI Boston? Explore the full range of sponsorship opportunities by downloading the RESI Sponsorship Brochure, or visit the RESI Sponsors page to learn more. To discuss a customized sponsorship package that aligns with your business development goals, contact sales@lifesciencenation.com. Sponsorship packages can be tailored to maximize your visibility, thought leadership, and connections within the global life science investment community.

Tags: , , , , , , , , , , , , ,

Discover the Innovators: 14 Pitch Sessions Showcasing Emerging Life Science Companies 

9 Jun

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

The Innovator’s Pitch Challenge (IPC) returns to RESI San Diego with an exciting lineup of 14 pitch sessions showcasing emerging companies from across the life science ecosystem. Finalists represent a broad range of innovation spanning Therapeutics, Medical Devices, Diagnostics, and Digital Health, highlighting the technologies shaping the future of healthcare.

These sessions provide RESI attendees with a unique opportunity to discover breakthrough technologies and engage directly with the entrepreneurs driving them forward. Each company will present in front of a panel of active investors and strategic partners, participate in live Q&A discussions, and receive valuable feedback from industry experts.

In addition to presenting during their assigned pitch session, all IPC finalists will showcase their companies in the RESI exhibition area through dedicated pitch posters. This format allows attendees to explore innovative technologies at their own pace, connect directly with company leadership, and schedule follow-up discussions with promising startups throughout the conference.

The Innovator’s Pitch Challenge culminates with the presentation of RESI Cash awards, recognizing standout companies from across the competition. Award recipients will also be featured in Life Science Nation’s Next Phase newsletter, providing additional visibility among the global RESI community.

More than a competition, the Innovator’s Pitch Challenge serves as a platform for fundraising companies to gain visibility, validate their value proposition, and build meaningful relationships with investors, strategic partners, and industry leaders from around the world.

See the full list of pitching companies below:

Apply to Pitch at RESI Boston

Tags: , , , , , , , , , , , , ,

Innovator’s Pitch Challenge: Where Deals Start

19 May

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

At most conferences, startup pitch competitions are treated as side programming. Founders present a deck, judges select winners, applause follows, and the event moves on.

At RESI San Diego, the Innovator’s Pitch Challenge (IPC) is designed differently.

The IPC is not simply about winning a competition. It is designed to help early-stage life science companies generate investor attention, create business development momentum, and accelerate conversations that continue long after the presentation ends.

For many companies, that interaction becomes the most valuable part of the experience.

“The discussions also felt far more relationship-driven than transactional,” said Sian Farrell, CEO of StimOxyGen. “Conversations extended beyond the pitch itself and focused on clinical strategy, regulatory pathways, commercialization, and long-term value creation.”

Unlike standalone pitch competitions, the IPC is integrated directly into the larger RESI partnering ecosystem. Participating companies also receive partnering access, poster presentation visibility, and exposure throughout the conference environment, creating multiple opportunities for follow-up interaction.

“The combination of the presentation and the partnering platform made a significant difference,” said Bram de Moor, CEO of You2Yourself. “RESI brought us into direct contact with European and transatlantic life science investors who specifically seek early-stage diagnostic and biomarker companies — an audience difficult to reach through cold outreach.”

The IPC also introduces an interactive audience component through “RESI cash,” distributed to attendees during registration. Participants allocate their RESI cash to the companies they believe demonstrate the strongest potential, creating additional visibility and engagement throughout the event.

For founders navigating today’s capital environment, opportunities that combine exposure with concentrated investor access are increasingly valuable.

As fundraising conditions continue to demand stronger differentiation and clearer commercialization pathways, platforms that help companies sharpen messaging and generate high-quality investor interaction have become increasingly important.

At RESI, the IPC is intended to serve exactly that purpose.

Selected companies receive:

  • Two 5-day RESI registrations
  • A six-minute company presentation followed by seven minutes of investor Q&A
  • Poster presentation space
  • Full partnering access
  • Exposure to investors, strategic partners, and pharma business development teams throughout Convention Week

For many founders, the IPC becomes more than a presentation opportunity. It becomes the place where investor conversations begin, strategic relationships form, and fundraising momentum accelerates.

Applications for the Innovator’s Pitch Challenge at RESI San Diego are currently open, with limited presentation slots remaining.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , ,

Oncovita: A Novel Measles-Based Approach to Unlock Immunotherapy in Solid Tumors 

5 May

By Rahul Shetty, Project Management & BD Associate, LSN

Max-Braht-HeadshotIn oncology, one of the most persistent challenges is not a lack of therapeutic innovation, but a fundamental biological limitation: many tumors remain invisible to the immune system. While immunotherapies such as checkpoint inhibitors have transformed treatment paradigms, a significant proportion of cancers, often referred to as “cold” tumors, fail to respond because they simply are not recognized as threats.

Oncovita, a France-based biotechnology company, is addressing this challenge with a novel approach rooted in engineered measles virotherapy. By leveraging the natural biology of the measles vaccine virus, the company aims to expose tumors to immune attack, effectively converting immunologically silent cancers into targets the body can detect and destroy.

This approach is particularly relevant in pleural mesothelioma, one of the deadliest solid tumors, where survival is often measured in months and treatment options remain extremely limited. Its immunologically silent nature makes it largely invisible to immune surveillance and resistant to existing immunotherapies, leaving patients with few effective options.

At the core of Oncovita’s platform is MVdeltaC, an engineered measles vaccine virus designed for intratumoral administration. Many tumors, including mesothelioma, overexpress CD46 – the receptor used by the measles virus to enter cells, providing a natural mechanism for selective targeting. Once inside the tumor, MVdeltaC triggers immunogenic tumor cell death and immune activation by releasing danger signals and tumor antigens, ultimately priming T cells to recognize and attack cancer. In doing so, it converts “cold” tumors into “hot” ones, enabling both local and systemic immune responses.

The use of measles vaccine as a therapeutic backbone offers several advantages. The live attenuated vaccine has been administered to more than four billion people worldwide, establishing a strong safety profile. It replicates in the cytoplasm without integrating into host DNA and is known to stimulate both innate and adaptive immunity, making it well suited for cancer immunotherapy.

Evidence supporting this approach includes a documented remission in a patient with triple-negative breast cancer treated with a measles-based therapy, along with preclinical data showing complete tumor regressions, long-term survival, and systemic immune activation across multiple aggressive tumor models. MVdeltaC has also demonstrated strong potential in combination with checkpoint inhibitors, further expanding its therapeutic relevance.

Oncovita is advancing MVdeltaC with an initial focus on pleural mesothelioma, supported by FDA & EMA Orphan Drug Designation and a clear regulatory pathway. From there, the company plans to expand into triple-negative breast cancer and additional solid tumors, using a stepwise strategy that builds early clinical validation before scaling into larger markets. This stepwise approach allows the company to generate early clinical proof-of-concept in a high-need population before expanding into broader oncology indications. With approximately 9,000 eligible patients annually across the U.S., Europe, and Japan in its initial indications and a significantly larger addressable market across solid tumors, the long-term opportunity is substantial.

Oncovita’s progress is supported by a multidisciplinary team with expertise spanning virology, immunotherapy, and clinical oncology. The company collaborates with leading institutions and key opinion leaders, including experts from Institut Gustave Roussy and MD Anderson Cancer Center, reinforcing the scientific and clinical foundation of its program.

As immunotherapy continues to evolve, enabling the immune system to recognize cancer may be just as important as enhancing its response. Oncovita’s measles-based virotherapy represents a compelling approach to solving this challenge, offering the potential to expand immunotherapy to patients who currently have limited treatment options.

Learn More & Connect

To learn more about Oncovita, visit: https://www.oncovita.fr/

To connect directly with CEO Stephane Altaba, reach out here: stephane.altaba@oncovita.fr

Tags: , , , , , , , , , , , , , , , ,

← Older Entries